Isryl-M3 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, increasing insulin sensitivity in peripheral tissues, and reducing intestinal glucose absorption. The prolonged-release formulation allows for sustained drug release, promoting better patient compliance and stable plasma drug levels. Isryl-M3 Forte Tablet PR is indicated for adult patients inadequately controlled by diet and exercise alone or by monotherapy with either agent. It is essential to initiate therapy under medical supervision, with dosage adjustments based on glycemic response and tolerance. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as the risk of hypoglycemia due to glimepiride. Caution is advised in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction, metabolic acidosis, and hypersensitivity to components. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy to ensure safety and efficacy.